Join me!

My team worked in collaboration with Bill Dalton, Kim Blackwell, Atul Butte / India Hook Barnard, Nancy Davidson and Sharon Terry to create a program that touches every component of precision medicine while bringing together all of its key stakeholders.

Leading participating institutions including Stanford Health Care, UCSF, Duke Health, Duke University, Johns Hopkins University, University of Michigan and more will share their learnings and experiences and their successes and challenges, as they make precision medicine the new standard of care for all.

More than 400 speakers, 5 tracks, 60 sessions, and 2,000+ attendees focusing on:

  • AI/Machine Learning advancements and applications
  • Genomic Medicine in the clinic
  • Immunotherapy Advancements
  • Next-generation sequencing developments and applications
  • The importance of Data Sharing and Data Privacy
  • The rise of New Healthcare Models that revamp health care
  • And many other relevant sessions on Precision Medicine, including liquid biopsy applicationspopulation genome initiativesbig data analysis, real-world evidence for decision-making, along with the much-discussed and debated CRISPR-Cas9 genome editing tool

My team and collaborators worked diligently to bring you this timely conference. I hope to see you there, maybe we can chat in person.
See a preview of the conference agenda below or just shoot me back an email if you are curious.

Best regards,
Tal Behar
Co-Founder & President

PMWC Silicon Valley – Santa Clara Convention Center – January, 20-23

Celebrating 10 Years of Precision Medicine Innovation

PREVIEW of PMWC PROGRAM:

  • Awards ceremony honoring Dr. Carl June (University of Pennsylvania), Dr. Feng Zhang (Broad Institute), Sharon Terry (Genetic Alliance), and George D. Yancopoulos (Regeneron) at the Luminary and Pioneer Award Ceremony on Monday January 20, 2019.
  • Exhibition with over 60 emerging and established companies and organizations showcasing their products and services. Find the complete list of exhibiting companies here.

DAY 1:
Immunotherapy

  • 12 sessions that discuss novel hematologic cancer immunotherapies, IO collaborative group trials, predictive biomarkers and new therapies, regulating T-cells and their response to cancer, combinations with other modalities, beyond PD-(L)1 blockades, genetically engineered T cell-based therapies, cancer neoantigen vaccines, cell-based immunotherapies, an emerging tool for immune response monitoring, and IO intellectual properties.
  • Emerging Therapeutics and Immunotherapy showcase with over 40 companies presenting their latest technologies in cell-based immunotherapies, cancer vaccines, patient selection processes, and more.
  • Fireside chat:
    • Carl June (University of Pennsylvania) and Kim Blackwell (Eli Lilly)
  • Keynotes: Feng Zhang (Broad Institute) and George D. Yancopoulos (Regeneron)
  • Presenters include: Kimberly Blackwell (Lilly), Lawrence Fong (UCSF), David Miklos (Stanford), Charles Perou (GeneCentric Therapeutics), Dan Chen, (IGM Biosciences), Mark Raffeld (NIH), Kara Davis (Stanford University), Andrew Allen (Gritstone Oncology), Catherine Polizzi (Morrison & Foerster), Scott Pruitt (Merck), Theresa LaVallee (Parker Institute), George Karlin-Neumann (Bio-Rad), Kurt A. Schalper (Yale University), Chris Linthwaite (Fluidigm), Silvia Chiara Formenti (Weill Cornell Medicine), Adrian Bot (Kite s Gilead Company), Timothy Looney (Thermo Fisher Scientific), Nicholas Dracopoli (PGDx), Andrea van Elsas (Aduro Biotech), and Carl June (University of Pennsylvania).

DAY 1:
Cancer Centers

  • 14 presenters from leading Cancer Centers in the US discuss applying precision oncology through Molecular Tumor Board. They will share their learnings and the resulting added value to their institutions and medical communities, as well as the challenges they have overcome.
  • Keynotes: James M. Ford (Stanford)
  • Presenters include: Shridar Ganesan (Rutgers Cancer Institute of New Jersey), Boris Pasche (Wake Forest University), Stephen B. Gruber (USC Norris Comprehensive Cancer Center), Lincoln Nadauld (Intermountain Health), Anna Berry (Swedish Cancer Institute), Daniel Catenacci (University of Chicago), Alejandro Sweet-Cordero (UCSF), David Spigel (Sarah Cannon), Sheldon Greenfield (University of California, Irvine), Asaf Rotem (Dana-Farber Cancer Institute).

DAY 1 & 2:
AI and Machine Learning

  • 13 sessions that address how AI is applied to drug discovery/ development and data sciences, how it aids clinical decision making, how it is applied to precision imaging for prediction, how it drives clinical trial design and patient selection, what the requirements are for a scalable AI/machine learning systems framework, and an AI/Machine Learning investment perspective.
  • AI and Data Science showcases with 50 companies presenting their latest innovations in pre-clinical and clinical drug discovery, patient diagnosis and treatment, and scalable systems frameworks.
  • Presenters include: Atul Butte (UCSF), Deborah Schrag (Harvard Medical School), Vijay Pande (Andreessen Horowitz), Daphne Koller (Insitro), Aris Baras (Regneron), Jessica Mega (Verily), George Asimenos (DNAnexus), Richard Wender (American Cancer Society), Michael Pellini (Section 32), Andy Beck (PathAI), David Shaywitz (Takeda Ventures), Lee Pierce (Sirius Computer Solutions), Kim Branson (Genentech), Vipin Gopal (Eli Lilly and Company), Malvina Eydelman (FDA), Michael D. Abramoff (IDx), Lizzie Dorfman (Google AI), Suzanne Belinson (Tempus), John McHutchison (Gilead), Lon Cardon (BioMarin), Kerrie Holley (Optum), Julie Iskow (Medidata), and many more.

DAY 2:
NGS

  • 10 sessions that address various aspects of genomic medicine, including population-based biobanking, cancer phenotyping and screening, emerging applications, ethical implications of using whole exome sequencing in prenatal and young children, performing genomics at scale, ensuring access to genetic counseling, and why we need to focus on healthy people as well as sick people in genomic medicine.
  • Company showcases with over 60 companies presenting:
    • Clinical & Research Tools with 28 presenters showcasing their latest innovations that represent breakthroughs in genetic health, rare disease, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies that empower rapidly evolving genomic revolution.
  • Fireside Chat Francis deSouza (Illumina) & Emily Leproust (Twist Bioscience)
  • Presenters Include: Steve Quake (Stanford), Catherine Brownstein (Boston Children Hospital), Hanlee Ji (Stanford), Allison Ballmer (Agilent,) Carlos Bustamante (Stanford University), Jeffrey Edward Miller (Invivoscribe), J. Michael Cherry (Stanford University), Chad Robins, Adaptive Biotechnologies, Brady Davis (DNAnexus), Benedict Paten (UC Santa Cruz), James H. Godsey (Thermo Fisher Scientific), Ted Goldstein (UCSF) and Francis deSouza (Illumina).

DAY 2
NEW MODELS

  • 6 sessions that presents new models in health care to improve patient care:
    • Ecosystem of Shared Value
    • New Hospital-administrated Drugs Supply Model
    • New Model For Primary Care
    • New Preventive Care Models
  • Fireside Chat: Trent Haywood (Blue Cross Blue Shield Institute) and John Hornberger (Genomic Health)
  • Presenters Include: Jennifer Splansky Juster (Collective Impact Forum), Gertjan Bartlema (Celularity), William Dalton (M2Gen), Jenny Isaacson (Pancreatic Cancer Action Network), Dan Liljenquist (Intermountain Healthcare / Civica Rx), Amir Dan Rubin (One Medical), Ralph Snyderman (Duke University), Amy Compton-Phillips (Providence St. Joseph Health), Catherine Reinis Lucey (UCSF), J. Craig Venter (JCVI), Brook Byers (KPCB).

DAY 2 & 3:
Genomic Medicine

  • 10 sessions that address various aspects of genomic medicine, including population-based biobanking, cancer phenotyping and screening, emerging applications, ethical implications of using whole exome sequencing in prenatal and young children, performing genomics at scale, ensuring access to genetic counseling, and why we need to focus on healthy people as well as sick people in genomic medicine.
  • Company showcases with over 60 companies presenting:
    • The Genomic Profiling Showcase – commercial advancements and innovations in DNA/RNA sequencing (methods and instruments)
    • The Clinical Dx Showcase – commercial advancements in expedited, cost-effective, and accurate clinical diagnostics
    • Liquid biopsy Showcase – commercial advancements and developments of screening minimally-invasive tests for oncology, immunotherapy, and other areas
  • Presenters include: Harold Paz (Aetna), Keith Yamamoto (UCSF), Erica Ramos (Geisinger), Randy Scott (Invitae), Nancy Davidson (Fred Hutchinson Cancer Research Center), Shannon McCall (Duke University), Minnie Sarwal (UCSF), Mickey Kertesz (Karius), Joe Zhang (Burning Rock Dx), Jean-Francois Martini (Pfizer), Akhil Saklecha (Cleveland Clinic Ventures), Yuri A. Fesko (Quest Dx), Helmy Eltoukhy (Guardant Health), Richard Schilsky (ASCO), Atul Sharan (CellMaxLife), Gordon Mills (OHSU), Cornelius Boerkoel (Sanford Health), Aleksandar Rajkovic (UCSF Health), Varda Shalev (Maccabi Medical Center, Israel), Gad Rennert, Clalit Health Services, Israel, Hakan Sakul (Pfizer), Ellen Beasley (Genomic Health) and many more.

DAY 3
Patient Data

  • 11 sessions on the use of new technologies that provide tremendous benefits for both patients and providers, and how to address the increased risks to  security and privacy of patient data that comes with increased sharing. Special focus will be placed on successful use cases and how to overcome obstacles to patient data sharing.
  • Fireside chat:
    • Eric Dishman, NIH & Sharon Terry, Genetic Alliance
  • Keynote: Seema Verma, CMS
  • Presenters include: Jamie Ferguson (Kaiser Permanente), Michael Halaas (Stanford School of Medicine), Tom Insel (MindStrong), Mitch Lunn (UCSF), Andreas Kogelnik (Open Medicine Institute), William Dalton (M2Gen), Bastian Greshake Tzovaras (Open Humans), Jason Bobe (Icahn Institute), Dawn Barry (LunaDNA), George Komatsoulis (CancerLinQ), Patricia Goede (XIFIN), Julie Ramage, (Pfizer), Rebecca Owens, TapRooT, Deven McGraw (Ciitizen) and more.

FULL PROGRAM LINK

Interview with Ken Bloom of Ambry Genetics

Q: Tell us more about your organization/company. What patient population are you serving and which services are you specializing in?

A: Ambry Genetics is a recognized leader in high quality complex genetic testing. We seek to find the genomic cause or contributors to rare diseases, abnormal phenotypes and hereditary disorders.

Read More

Interview with Lee Pierce of Sirius Computer Solutions

Q: What is the state of big data and analytics in healthcare, and how to best use the reams of data available?

A: More than ever, Healthcare organizations are achieving measurable value through use of their data and analytics assets. There is more raw material available than ever to create value. This raw material is the data flowing from internal systems and applications and also from devices and systems external to healthcare organizations.

Read More

Interview with Anita Nelsen of PAREXEL

Q: There are various new, emerging technologies that bring us closer towards a cure for life-threatening disorders such as cancer, HIV, or Huntington’s disease. Prominent examples include the popular gene editing tool CRISPR or new and improved cell and gene therapies. By when can we expect these new technologies being part of routine clinical care?

A: Today’s emerging technologies are making the promise of individualized treatment a reality.

Read More

Interview with Ilan Kirsch of Adaptive Biotechnologies

Q: The Nobel Prize in Medicine was awarded recently to James Allison and Tasuku Honjo for their work on unleashing the body’s immune system to attack cancer, a breakthrough that has led to an entirely new class of drugs and brought lasting remissions to many patients who had run out of options. The Nobel committee hailed their accomplishments as establishing “an entirely new principle for cancer therapy.” What is your first-hand experience the impact that those new drugs had on patients?

A: For decades cancer was viewed as solely a cell-autonomous condition.

Read More

BMS buys Celgene | Lilly buys Loxo Oncology – Does this Signal a Return to Strong Deal-Making Activities in 2019?

Bristol-Myers Squibb’s blockbuster $74B deal to buy Celgene creates an oncology powerhouse amid industrywide excitement about the rapidly evolving science and explosive growth of the sector. The agreement could signal a return to deal-making for the pharmaceutical industry in the $133B global oncology therapeutics market.

Read More

Interview with Gini Deshpande of NuMedii

Q: What need is NuMedii addressing?

A: NuMedii, has been pioneering the use of Big Data, artificial intelligence (AI) and systems biology since 2010 to accelerate the discovery of precision therapies to address high unmet medical needs. Artificial Intelligence approaches are a natural fit to harness Big Data as they provide a framework to ‘train’ computers to recognize patterns and sift through vast amounts of new and existing genomic

Read More

Interview with Minnie Sarwal of UCSF

Q: Genomic medicine is entering more hospitals and bringing with it non-invasive technology that can be used to better target and treat diseases. What are some key milestones that contributed to this trend?

A: Completion of complete sequence data from the human genome project, and the advances in proteomic, microRNA and epigenetic assays added a layer of pathway biology to the understanding of human diseases.

Read More

Interview with Shidong Jia of Predicine

Q: Once sequencing has been validated as a clinical solution via trusted workflows, and coinciding with the technological developments driving costs lower, we can expect accelerated human genome profiling for clinical Dx. How soon, do you think, will we see accelerated growth and what can we expect?

A: We will see accelerated human genome profiling for clinical Dx in 2019 and the coming years as more biomarker-based cancer drugs are gaining approval.

Read More

Interview with Iya Khalil of GNS Healthcare

Q: Artificial intelligence (AI) techniques have sent vast waves across healthcare, even fueling an active discussion of whether AI doctors will eventually replace human physicians in the future. Do you believe that human physicians will be replaced by machines in the foreseeable future? What are your thoughts?

A: I think that there’s a lot of speculation and uncertainty around AI, but I don’t foresee a time when we won’t need physicians.

Read More

Interview with Ilya Michael Rachman of Immix Biopharma Inc.

Q: The Nobel Price in Medicine was awarded recently to James Allison and Tasuku for their work on unleashing the body’s immune system to attack cancer, a breakthrough that has led to an entirely new class of drugs and brought lasting remissions to many patients who had run out of options. The Nobel committee hailed their accomplishments as establishing “an entirely new principle for cancer therapy.” Besides CAR T-cell therapy what do you think next generation immunotherapies will look like to successfully combat cancer?

A: The next generation of immunotherapies will build on the insights discovered by immunologists like James Allison and Tasuku Honjo and extend them to modify the body’s response to tumors.

Read More

Join me to Kick off PMWC Silicon Valley in the Santa Clara Convention Center, Focusing on Every Element of Precision Medicine

My team worked in collaboration with Bill Dalton, Kim Blackwell, Atul Butte / India Hook Barnard, Nancy Davidson and Sharon Terry to create a program that touches every component of precision medicine while bringing together all of its key stakeholders. Leading participating institutions including Stanford Health Care, UCSF, Duke Health, Duke University, John Hopkins University, University of Michigan and more will share their learnings and experiences and their successes and challenges, as they make precision medicine the new standard of care for all.

Read More

Interview with Dominic Eisinger of Myriad RBM

Q: The Nobel Price in Medicine was awarded recently to James Allison and Tasuku for their work on unleashing the body’s immune system to attack cancer, a breakthrough that has led to an entirely new class of drugs and brought lasting remissions to many patients who had run out of options. The Nobel committee hailed their accomplishments as establishing “an entirely new principle for cancer therapy.” Besides CAR T-cell therapy what do you think next generation immunotherapies will look like to successfully combat cancer?

A: Next generation immunotherapies include CAR-Ts, TCRs, cancer vaccines, ADCs, bi-specific antibodies, and checkpoint inhibitors.

Read More

2018 Year in Review Milestones: Stakeholder Partnerships Carving Precision Medicine’s Future

2018 has clearly been a year when significant opportunities intersected with strong partnerships to yield advancements. In particular, the clinical advancements that were realized are a testimony to stakeholders working together to deliver on promises affecting major aspects of precision medicine. 2018 has clearly been a year when significant opportunities intersected with strong partnerships to yield advancements.

Read More

Interview with Lisa Alderson of Genome Medical

Q: Tell us a little bit about Genome Medical. What market need is Genome Medical addressing and how?

A: Genome Medical is a telegenomics company that is bridging the gap between available, genetic expertise and the clinical application of genomics.

Read More

Interview with Nasir Bhanpuri of Virta Health

Q: What need is Virta Health addressing?

A: Virta Health delivers an evidence-based treatment to safely and sustainably reverse type 2 diabetes without the use of medications or surgery. In the U.S. alone, type 2 diabetes and prediabetes affects 115 million people, and the economic burden is well-over $300 billion and growing.

Read More
Johns Hopkins
University Of Michigan

The Precision Medicine World Conference (PMWC), in its 17th installment, will take place in the Santa Clara Convention Center (Silicon Valley) on January 21-24, 2020. The program will traverse innovative technologies, thriving initiatives, and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.

See 2019 Agenda highlights:

  • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • AI & Data Science Showcase
    • Clinical & Research Tools Showcase
    • Clinical Dx Showcase
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Digital Health/Health and Wellness
    • Digital Phenotyping
    • Diversity in Precision Medicine
    • Drug Development (PPPs)
    • Early Days of Life Sequencing
    • Emerging Technologies in PM
    • Emerging Therapeutic Showcase
    • FDA Efforts to Accelerate PM
    • Gene Editing
    • Genomic Profiling Showcase
    • Immunotherapy Sessions & Showcase
    • Implementation into Health Care Delivery
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Microbial Profiling Showcase
    • Microbiome
    • Neoantigens
    • Next-Gen. Workforce of PM
    • Non-Clinical Services Showcase
    • Pharmacogenomics
    • Point-of Care Dx Platform
    • Precision Public Health
    • Rare Disease Diagnosis
    • Resilience
    • Robust Clinical Decision Support Tools
    • Wellness and Aging Showcase

See 2019 Agenda highlights:

    • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • AI & Data Science Showcase
      • Clinical & Research Tools Showcase
      • Clinical Dx Showcase
      • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
      • Digital Health/Health and Wellness
      • Digital Phenotyping
      • Diversity in Precision Medicine
      • Drug Development (PPPs)
      • Early Days of Life Sequencing
      • Emerging Technologies in PM
      • Emerging Therapeutic Showcase
      • FDA Efforts to Accelerate PM
      • Gene Editing / CRISPR
      • Genomic Profiling Showcase
      • Immunotherapy Sessions & Showcase
      • Implementation into Health Care Delivery
      • Large Scale Bio-data Resources to Support Drug Development (PPPs)
      • Microbial Profiling Showcase
      • Microbiome
      • Neoantigens
      • Next-Gen. Workforce of PM
      • Non-Clinical Services Showcase
      • Pharmacogenomics
      • Point-of Care Dx Platform
      • Precision Public Health
      • Rare Disease Diagnosis
      • Resilience
      • Robust Clinical Decision Support Tools
      • Wellness and Aging Showcase
  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 2000+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine
Get Updates
Sign up for occasional updates on upcoming conferences, news, and other information.
We respect your privacy and will never share your email with anyone.
Something went wrong, please verify your input.
Thank you for signing up!

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

Here is your coupon code: newsletter-5percentoff-THISWEEKONLY